{"nctId":"NCT00258154","briefTitle":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","startDateStruct":{"date":"2006-02"},"conditions":["Rotavirus Disease"],"count":403,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Rotavirus Vaccine, Live, Oral, Pentavalent","Biological: Comparator: Infanrix(tm) Hexa"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Comparator: placebo","Biological: Comparator: Infanrix(tm) Hexa"]}],"interventions":[{"name":"Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":[]},{"name":"Comparator: placebo","otherNames":[]},{"name":"Comparator: Infanrix(tm) Hexa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infant per investigator, 6 through 12 weeks of age\n\nExclusion Criteria:\n\n* History of congenital abdominal disorders, intussusception, or abdominal surgery\n* Known or suspected impairment of immunological function\n* Known hypersensitivity to any component of the rotavirus vaccine\n* Prior administration of any rotavirus vaccine\n* Known hypersensitivity or contraindication to any component of INFANRIX(tm) hexa\n* Any infant born from a known HBsAg-positive mother\n* Prior administration of any oral polio vaccine\n* Receipt of one or more doses of inactivated poliovirus vaccine, diptheria, tetanus and acellular pertussis vaccine, diptheria, tetanus and pertussis vaccine, Haemophilus influenzae type b vaccine, or any hepatitis B vaccine prior to the first vaccination, or receipt of any vaccines with these antigens at any time during the course of the study\n* Fever, with a rectal temperature greater than or equal to 38.1 degree C (greater than or equal to 100.5 degree F) at the time of immunization\n* History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive\n* Clinical evidence of active gastrointestinal illness\n* Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination\n* Infants residing in a household with an immunocompromised person\n* Prior receipt of a blood transfusion or blood products\n* Participation in another clinical study within 42 days before the beginning or anytime during the duration of the current clinical study\n* Any infant who cannot be adequately followed for safety by a contact visit\n* History of seizure disorders or prior history followed for safety by a contact visit\n* Any condition that, in the opinion of the investigator, may interfere with the evaluation of the study objectives","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1","description":"Geometric Mean Titer (GMT)/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"13.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 1 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"18.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg , at 42 Days After a 3-dose Regimen","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ in relation to anti-hepatitis B surface antigen HBsAg at 42 days after 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227.8","spread":null},{"groupId":"OG001","value":"261.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP, Predose 1","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at start of 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"204.3","spread":null},{"groupId":"OG001","value":"189.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Anti-polyribosylribitol Phosphate PRP at 42 Days After a 3-dose Regimen","description":"GMT/antibody responses to RotaTeq™ and INFANRIX™ hexa in relation to serum anti-polyribosylribitol phosphate PRP at 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1316","spread":null},{"groupId":"OG001","value":"1400","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 1 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 1 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa , 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"160.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 2 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"12.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 2 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 2 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"69.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of Poliovirus Type 3 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"7.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Poliovirus Type 3 When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of Poliovirus Type 3 in subjects with even allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"222.9","spread":null},{"groupId":"OG001","value":"263.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of diphtheria toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Diphtheria Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of diphtheria toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of tetanus toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Tetanus Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of tetanus toxoid in subjects with odd allocation numbers, receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis FHA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis FHA When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis FHA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"78.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis Pertactin in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Pertactin When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis Pertactin in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.6","spread":null},{"groupId":"OG001","value":"108.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, Predose 1","description":"GMT of pertussis toxoid in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of INFANRIX™ Hexa in Relation to Serum Antibody Levels to Pertussis Toxoid When Administered Concomitantly With RotaTeq™, 42 Days After a 3-dose Regimen","description":"GMT of pertussis toxoid in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"28.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1","description":"GMT of serotype G1 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G1 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, 42 Days After a 3-dose Regimen","description":"GMT of serotype G1 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115.7","spread":null},{"groupId":"OG001","value":"8.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa, Predose 1","description":"GMT of serotype G2 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa at the start of a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G2 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G2 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype G3 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G3 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G3 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype G4 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype G4 in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype G4 in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serotype P1A in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null},{"groupId":"OG001","value":"33.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serotype P1A in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serotype P1A in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa Predose 1","description":"GMT of serum anti-rotavirus IgA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa Predose 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Neutralizing Antibody (SNA) Response to Serum Anti-rotavirus IgA in Patients Receiving RotaTeq™ Concomitantly With INFANRIX™ Hexa 42 Days After a 3-dose Regimen","description":"GMT of serum anti-rotavirus IgA in subjects receiving RotaTeq™ + INFANRIX™ hexa compared to those receiving placebo + INFANRIX™ hexa 42 days after a 3-dose regimen","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160.0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":201},"commonTop":["Pyrexia","Diarrhoea","Vomiting","Enteritis","Rhinitis"]}}}